1. Home
  2. KNRX vs EVAX Comparison

KNRX vs EVAX Comparison

Compare KNRX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNRX

KNOREX LTD. Class A Ordinary Shares

HOLD

Current Price

$0.48

Market Cap

30.3M

Sector

Technology

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$3.90

Market Cap

32.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNRX
EVAX
Founded
2009
2008
Country
Singapore
Denmark
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.3M
32.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KNRX
EVAX
Price
$0.48
$3.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
100.1K
27.1K
Earning Date
06-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$2.11
52 Week High
$3.45
$12.15

Technical Indicators

Market Signals
Indicator
KNRX
EVAX
Relative Strength Index (RSI) 22.31 41.45
Support Level N/A $3.32
Resistance Level $1.46 $4.65
Average True Range (ATR) 0.07 0.18
MACD -0.01 -0.03
Stochastic Oscillator 27.80 19.64

Price Performance

Historical Comparison
KNRX
EVAX

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: